Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by askretkaon Aug 18, 2022 3:36pm

265 Views

Post# 34905579

15$ US Target maintained H.C. Wainwright 18 Aug 2922

In a report released today,Patrick Trucchiofrom H.C. Wainwright maintained a Buy rating on Oncolytics Biotech (ONCYResearch Report), with a price target of$15.00. The companys shares closed yesterday at $1.27

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals